金吾财讯 | 据外媒报道，多间跨国药企正寻求通过加入中国商业健康保险目录，扩大其创新高价药物在内地的销售。根据国家医疗保障局公布的文件，礼来(LLY)、诺和诺德及辉瑞(PFE)等公司已提交申请。今年首度推出的商业健康保险目录，专门收录因价格过高未能进入国家医保、但推荐由商业保险覆盖的创新药品，允许药品以较小折扣幅度获得报销，为跨国企业开拓新销售渠道。而此前药企仅有两种选择，只可大幅降价进入国家医保目录，或局限于规模有限的私营市场。报道指，共有121种药物通过初步筛选进入候选名单，涵盖畅销药及罕见病治疗药物，最终结果预计10至11月公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.